Azathioprine and hydroxychloroquine overdose in Sjögren's syndrome patient with hypocalcemia: a case report.
Azathioprine
Hydroxychloroquine
Overdose
Sjögren’s syndrome
Journal
Journal of medical case reports
ISSN: 1752-1947
Titre abrégé: J Med Case Rep
Pays: England
ID NLM: 101293382
Informations de publication
Date de publication:
27 Feb 2024
27 Feb 2024
Historique:
received:
24
10
2023
accepted:
17
01
2024
medline:
27
2
2024
pubmed:
27
2
2024
entrez:
26
2
2024
Statut:
epublish
Résumé
Hydroxychloroquine and azathioprine have been routinely used to control and treat primary and secondary Sjögren's syndrome, which potentially triggered some overdoses by these drugs. Toxicity from hydroxychloroquine and azathioprine manifests in the form of cardiac conduction abnormalities, nausea, vomiting, and muscle weakness. Recognizing these unique drug overdoses and management of these toxicities is important. This case report aims to expand our current understanding of these drug overdoses and their management and also underscores the importance of anticipating and identifying fewer common complications, such as hypocalcemia. A 34-year-old Persian woman with a history of Sjögren's syndrome presented to the emergency department 3.5-4 hours after an intentional overdose of hydroxychloroquine and azathioprine and severe hypotension and loss of consciousness. Although the patient was regularly taking other medications, such as fluoxetine, naproxen, and prednisolone, she explicitly clarified that these were not the substances involved in her overdose. Early investigations showed hypokalemia (2.4 mEq/L), hypocalcemia (7.5 mg/dL), and hypoglycemia (65 mg/dL). She was also diagnosed with metabolic acidosis and respiratory alkalosis. The electrocardiogram showed changes in favor of hypokalemia; other lab tests were run on the patient. Supportive treatments were applied, including rapid intravenous fluid dextrose 5%, normal saline, potassium chloride 30 mEq, and calcium gluconate 100 mg. The patient was managed and monitored overnight in the emergency room and recovered without residual side effects. Hydroxychloroquine and azathioprine toxicity are considered rare, but it is likely to increase in frequency given the prevalence and increase in autoimmune diseases and the increasing usage of these drugs in treating such diseases. We found hypocalcemia as the presentation to this patient, which needs further investigation into the probable mechanism. Clinicians need to consider the unique effects of hydroxychloroquine and azathioprine poisoning and initiate appropriate emergency interventions to improve the outcomes in similar patients.
Identifiants
pubmed: 38409169
doi: 10.1186/s13256-024-04390-w
pii: 10.1186/s13256-024-04390-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
76Informations de copyright
© 2024. The Author(s).
Références
Abarientos C, Sperber K, Shapiro DL, Aronow WS, Chao CP, Ash JY. Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy. Expert Opin Drug Saf. 2011;10:705–14.
doi: 10.1517/14740338.2011.566555
pubmed: 21417950
Gunja N, Roberts D, McCoubrie D, Lamberth P, Jan A, Simes DC, et al. Survival after massive hydroxychloroquine overdose. Anaesth Intensive Care. 2009;37:130–3.
doi: 10.1177/0310057X0903700112
pubmed: 19157361
Kyburz D, Brentano F, Gay S. Mode of action of hydroxychloroquine in RA—evidence of an inhibitory effect on toll-like receptor signaling. Nat Clin Pract Rheumatol. 2006;2:458–9.
doi: 10.1038/ncprheum0292
pubmed: 16951696
Watts C. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu Rev Immunol. 1997;15:821.
doi: 10.1146/annurev.immunol.15.1.821
pubmed: 9143708
Tanaka E, Taniguchi A, Urano W, Yamanaka H, Kamatani N. Pharmacogenetics of disease-modifying anti-rheumatic drugs. Best Pract Res Clin Rheumatol. 2004;18:233–47.
doi: 10.1016/j.berh.2004.02.006
pubmed: 15121042
Accapezzato D, Visco V, Francavilla V, Molette C, Donato T, Paroli M, et al. Chloroquine enhances human CD8+ T cell responses against soluble antigens . J Exp Med. 2005;202:817–28.
doi: 10.1084/jem.20051106
pubmed: 16157687
pmcid: 2212941
Imanova Yaghji N, Kan EK, Akcan S, Colak RA. Atmaca, Hydroxychloroquine sulfate related hypoglycemia in a non-diabetic COVİD-19 patient: a case report and literature review. Postgrad Med. 2021;133:548–51.
doi: 10.1080/00325481.2021.1889820
pubmed: 33583332
Della Porta A, Bornstein K, Coye A, Montrief T, Long B, Parris MA. Acute chloroquine and hydroxychloroquine toxicity: a review for emergency clinicians. Am J Emerg Med. 2020;38:2209–17.
doi: 10.1016/j.ajem.2020.07.030
pubmed: 33071096
pmcid: 7369162
Maltzman JS, Koretzky GA. Azathioprine: old drug, new actions. J Clin Invest. 2003;111:1122–4.
doi: 10.1172/JCI200318384
pubmed: 12697731
pmcid: 152947
Mahmood K, Khan AM, Ramanan AV, Martin K. Intentional overdose of azathioprine in a patient with systemic lupus erythematosus, Scott. Med J. 2013;58:e3–4.
Carney DM, Zukoski CF, Ogden DA. Massive azathioprine overdose: case report and review of the literature. Am J Med. 1974;56:133–6.
doi: 10.1016/0002-9343(74)90759-1
pubmed: 4588639
McWilliam M, Khan U. Azathioprine and the neurologist. Pract Neurol. 2020;20:69–74.
pubmed: 31444234
Chai PR, Ferro EG, Kirshenbaum JM, Hayes BD, Culbreth SE, Boyer EW, et al. Intentional hydroxychloroquine overdose treated with high-dose diazepam: an increasing concern in the COVID-19 pandemic. J Med Toxicol. 2020;16:314–20.
doi: 10.1007/s13181-020-00790-8
pubmed: 32514696
pmcid: 7278768
Page F. Treatment of lupus erythematosus with mepacrine. Lancet. 1951;258:755–8.
doi: 10.1016/S0140-6736(51)91643-1
Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y. Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol. 2012;42:145–53.
doi: 10.1007/s12016-010-8243-x
pubmed: 21221847
Al-Bari MAA. Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother. 2015;70:1608–21.
doi: 10.1093/jac/dkv018
pubmed: 25693996
Pareek A, Chandurkar N, Thomas N, Viswanathan V, Deshpande A, Gupta OP, et al. Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone. Curr Med Res Opin. 2014;30:1257–66.
doi: 10.1185/03007995.2014.909393
pubmed: 24669876
Fung HT, Lam KK, Wong OF, Lau B, Kam CW. A case of fatal hydroxychloroquine overdose, Hong Kong. J Emerg Med. 2007;14:53–7.
Ndukwu I, Ghahramani M. Hydroxychloroquine overdose presenting as acquired QT interval prolongation and torsade de pointes. J Am Coll Cardiol. 2017;69:2340.
doi: 10.1016/S0735-1097(17)35729-7
Goldman FD, Gilman AL, Hollenback C, Kato RM, Premack BA, Rawlings DJ. Hydroxychloroquine inhibit calcium signals in T cells: a new mechanism to explain its immunomodulatory properties, Blood. J Am Soc Hematol. 2000;95:3460–6.
A. Goyal, C. Anastasopoulou, M. Ngu and S. Singh, Hypocalcemia, 2017
W. Jasek, Austria-Codex, Vienna: Österreichischer Apothekerverlag 62 2007, pp. 5510–5511.
Radke JB, Kingery JM, Maakestad J, Krasowski MD. Diagnostic pitfalls and laboratory test interference after hydroxychloroquine intoxication: a case report. Toxicol Rep. 2019;6:1040–6.
doi: 10.1016/j.toxrep.2019.10.006
pubmed: 31673506
pmcid: 6816131
Yousuf SM, Alater AM, Alabdulla M, Osman M. False positive tramadol urine testing in patients taking fexofenadine: a tale of two consecutive cases. Case Rep Psychiatry. 2023. https://doi.org/10.1155/2023/4370648 .
doi: 10.1155/2023/4370648
pubmed: 36643013
pmcid: 9836806
Dakota S. Urine drug screening: minimizing false-positives and false-negatives to optimize patient care. US Pharm. 2016;41:26–30.